Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation.
Vandenberghe
P
P
Boeckx
N
N
Ronsyn
E
E
Decorte
R
R
Verhoef
G
G
Hagemeijer
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001854:Bone Marrow Cells / Q000473:pathology; D016026:Bone Marrow Transplantation; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy; D007958:Leukocyte Count; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate